Clobeta-GM

Clobetasol Topical (Clobeta-GM) scalp application also contains the following excipients: Carbomer, isopropyl alcohol, sodium hydroxide and purified water.

Clobetasol Topical (Clobeta-GM) cream also contains the following excipients: Glyceryl monostearate, cetostearyl alcohol, chlorocresol, sodium citrate, monohydrated citric acid, purified water, Arlacel 165, beeswax substitute 6621 and propylene glycol.

Clobetasol Topical (Clobeta-GM) ointment also contains the following excipients: Propylene glycol, white soft paraffin and sorbitan sesquioleate.

Miconazole Topical (Clobeta-GM) is a synthetic over-the-counter anti-fungal agent. It may come as a cream, powder, spray, or liquid aerosol, and is used to treat jock itch, athlete's foot and ringworm. It is sold under several brand names, most notably Tinactin (Schering-Plough Corporation) and Odor Eaters (Combe Incorporated). Other brands are Absorbine, Aftate, Desenex, Genaspor, NP 27, and Ting.

A component of Neomycin Topical (Clobeta-GM) that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). Neomycin Topical (Clobeta-GM) is a bactericidal aminoglycoside antibiotic that binds to the 30S ribosome of susceptible organisms. Binding interferes with mRNA binding and acceptor tRNA sites and results in the production of non-functional or toxic peptides.

Indication

Clobetasol Topical (Clobeta-GM)® Spray, 0.05% is a super-high potent topical corticosteroid formulation indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older. The total dosage should not exceed 50 g (59 mL or 2 fl. oz.) per week. Do not use more than 26 sprays per application or 52 sprays per day. Treatment should be limited to 4 consecutive weeks.

Patients should be instructed to use Clobetasol Topical (Clobeta-GM)® Spray, 0.05% for the minimum amount of time necessary to achieve the desired results see [Dosage and Administration (2)].

Use in patients under 18 years of age is not recommended because safety has not been established and because numerically high rates of HPA axis suppression were seen with other clobetasol propionate topical formulations.

Limitations of Use

Clobetasol Topical (Clobeta-GM)® Spray, 0.05% should not be used on the face, axillae, or groin. Clobetasol Topical (Clobeta-GM)® Spray, 0.05% should not be used if there is atrophy at the treatment site. Clobetasol Topical (Clobeta-GM)® Spray, 0.05% should not be used in the treatment of rosacea or perioral dermatitis.

Miconazole, an antifungal agent, is used for skin infections such as athlete’s foot and jock itch and for vaginal yeast infections.

This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Neomycin Topical (Clobeta-GM) tablets and other antibacterial drugs, Neomycin Topical (Clobeta-GM) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Suppression of Intestinal Bacteria

Neomycin Topical (Clobeta-GM) tablets are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel, e.g., preoperative preparation of the bowel. It is given concomitantly with erythromycin enteric-coated base.

Hepatic Coma (Portal-Systemic Encephalopathy)

Neomycin Topical (Clobeta-GM) has been shown to be effective adjunctive therapy in hepatic coma by reduction of the ammonia-forming bacteria in the intestinal tract. The subsequent reduction in blood ammonia has resulted in neurologic improvement.

Clobetasol is a topical (for the skin) steroid. It reduces the actions of chemicals in the body that cause inflammation, redness, and swelling.

Clobetasol Topical (Clobeta-GM) is used to treat the inflammation and itching caused by a number of skin conditions such as allergic reactions, eczema, and psoriasis.

Clobetasol Topical (Clobeta-GM) may also be used for purposes not listed in this medication guide.

Miconazole Topical (Clobeta-GM) is an antifungal medication. Miconazole Topical (Clobeta-GM) prevents fungus from growing on your skin.

Miconazole Topical (Clobeta-GM) (for the skin) is used to treat skin infections such as athlete's foot, jock itch, ringworm, tinea versicolor (a fungus that discolors the skin), and yeast infections of the skin.

Miconazole Topical (Clobeta-GM) may also be used for purposes not listed in this medication guide.

Neomycin Topical (Clobeta-GM) belongs to the family of medicines called antibiotics. Neomycin Topical (Clobeta-GM) preparations are used to help prevent infections of the skin. Neomycin Topical (Clobeta-GM) may be used for other problems as determined by your doctor.

Neomycin Topical (Clobeta-GM) preparations are available without a prescription.

Note: For proper dispensing of foam, hold the can upside down and depress the actuator.

Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam should be applied to the affected area twice daily, once in the morning and once at night. Invert the can and dispense a small amount of Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam (up to a maximum of a golf-ball-size dollop or one and a half capfuls) into the cap of the can, onto a saucer or other cool surface, or to the lesion, taking care to avoid contact with the eyes. Dispensing directly onto hands is not recommended (unless the hands are the affected area), as the foam will begin to melt immediately upon contact with warm skin. When applying Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam to a hair-bearing area, move the hair away from the affected area so that the foam can be applied to each affected area. Pick up small amounts with fingertips and gently massage into affected area until the foam disappears. Repeat until entire affected area is treated.

Apply the smallest amount possible that sufficiently covers the affected area(s). No more than one and a half capfuls of foam should be used at each application. Do not apply to face or intertriginous areas.

Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam is a super-high-potency topical corticosteroid; therefore, treatment should be limited to 2 consecutive weeks and amounts greater than 50 g/week should not be used. Use in pediatric patients under 12 years of age is not recommended. Unless directed by a physician, Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam should not be used with occlusive dressings.

Instructions for applying Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam

Apply Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam twice a day, once in the morning and once at night. Apply only enough to cover the affected areas. Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam should not be applied to the groin, armpits, or other skin fold areas.

To use Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam:

Before applying Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam for the first time, break the tiny plastic piece at the base of the can's rim by gently pushing back (away from the piece) on the nozzle.

Turn the can upside down.

Push the button to squirt a small amount of Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam into the cap of the can, onto a saucer or other cool surface, or your affected skin area. This amount should be no more than 1 ½ capfuls, about the size of a golf ball.

Do not squirt Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam directly onto your hands (unless your hands are the affected areas), because the foam will begin to melt right away on contact with your warm skin. If your fingers are warm, rinse them in cold water first. (Be sure to dry them thoroughly before handling the foam.)

If the can seems warm or the foam seems runny, run the can under cold water.

Using your fingertips, gently massage Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam into the affected areas until the foam disappears.

If you are treating areas with hair such as the scalp, move any hair away so that the foam can be applied directly to the affected areas.

Repeat the process until the affected areas are treated.

Keep the foam away from your eyes, as it will sting and may cause eye problems if there is frequent contact with your eyes. If the foam gets in your eyes, rinse them well with cold water right away. If the stinging continues, contact your doctor right away.

Wash your hands after applying Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam. Throw away any of the unused medicine that you squirted out of the can.

How supplied

Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam is supplied in 100 g (NDC 63032-031-00) and 50 g (NDC 63032- 031-50) aluminum cans.

Store at controlled room temperature 68-77°F (20-25°C).

WARNING

FLAMMABLE. AVOID FIRE, FLAME OR SMOKING DURING AND IMMEDIATELY FOLLOWING APPLICATION. Keep out of reach of children. Contents under pressure. Do not puncture or incinerate container. Do not expose to heat or store at temperatures above 120°F (49°C).

Manufactured for : Connetics Corporation, Palo Alto, CA 94304, USA. For additional information: 1-888-500-DERM or visit, www.Clobetasol Topical (Clobeta-GM) (clobetasol propionate).com. VersaFoam-HF is a trademark, and the V logo, the interlocking C design, Clobetasol Topical (Clobeta-GM) (clobetasol propionate) and Connetics are registered trademarks, of Connetics Corporation. January 2006. FDA revision date: 7/11/2006

Usual Adult Dose for Vaginal Candidiasis:

Vaginal suppository:

1 day therapy: Insert 1200 mg suppository intravaginally at bedtime for 1 day.

3 day therapy: Insert 200 mg suppository intravaginally at bedtime for 3 days.

7 day therapy: Insert 100 mg suppository intravaginally at bedtime for 7 days.

Vaginal cream:

Intravaginally:

2% cream: Insert one applicatorful intravaginally at bedtime for 3 to 7 days.

4% cream: Insert one applicatorful intravaginally at bedtime for 3 days.

Topically: Apply to external vulvar area twice a day for up to 7 days, as needed.

Usual Adult Dose for Tinea Corporis:

Topical cream, ointment, powder, spray, or tincture: Apply a thin layer to affected areas twice a day for 4 weeks.

Usual Adult Dose for Tinea Pedis:

Topical cream, ointment, powder, spray, or tincture: Apply a thin layer to affected areas twice a day for 4 weeks.

Usual Adult Dose for Cutaneous Candidiasis:

Topical cream, ointment, powder, or spray: Apply a thin layer to affected areas twice a day for 2 weeks.

Usual Adult Dose for Tinea Cruris:

Topical cream, ointment, powder, or spray: Apply a thin layer to affected areas twice a day for 2 weeks.

Usual Adult Dose for Tinea Versicolor:

Topical cream: Apply a thin layer to affected areas once a day.

Clinical and mycological clearing usually occur after 2 weeks of therapy.

Usual Pediatric Dose for Vaginal Candidiasis:

12 years or older:

Vaginal suppository:

1 day therapy: Insert 1200 mg suppository intravaginally at bedtime for 1 day.

3 day therapy: Insert 200 mg suppository intravaginally at bedtime for 3 days.

7 day therapy: Insert 100 mg suppository intravaginally at bedtime for 7 days.

Vaginal cream:

Intravaginally:

2% cream: Insert one applicatorful intravaginally at bedtime for 3 to 7 days.

4% cream: Insert one applicatorful intravaginally at bedtime for 3 days.

Topically: Apply to external vulvar area twice a day for up to 7 days, as needed.

Usual Pediatric Dose for Tinea Corporis:

2 years or older:

Topical cream, ointment, powder, spray, or tincture: Apply a thin layer to affected areas twice a day for 4 weeks.

Usual Pediatric Dose for Tinea Pedis:

2 years or older:

Topical cream, ointment, powder, spray, or tincture: Apply a thin layer to affected areas twice a day for 4 weeks.

Usual Pediatric Dose for Cutaneous Candidiasis:

2 years or older:

Topical cream, ointment, powder, or spray: Apply a thin layer to affected areas twice a day for 2 weeks.

Usual Pediatric Dose for Tinea Cruris:

2 years or older:

Topical cream, ointment, powder, or spray: Apply a thin layer to affected areas twice a day for 2 weeks.

Usual Adult Dose for Bowel Preparation

1 g orally every hour for 4 doses followed by 1 g every 4 hours for 5 doses

Alternate dosing: 6 g/day orally divided every 4 hours for 2 to 3 days

Usual Adult Dose for Hepatic Encephalopathy

4 to 12 g/day orally divided every 4 to 6 hours for 5 to 6 days

Usual Adult Dose for Hepatic Coma

4 to 12 g/day orally divided every 4 to 6 hours for 5 to 6 days

Usual Adult Dose for Diarrhea

3 g/day orally in 4 divided doses

Usual Pediatric Dose for Bowel Preparation

The safety and efficacy of Neomycin Topical (Clobeta-GM) in children less than 18 years of age has not been established. However, the use of Neomycin Topical (Clobeta-GM) may be appropriate is some situations.

Less than 1 month: 50 mg/kg/day orally divided every 6 hours

1 year to 18 years: 50 to 100 mg/kg/day orally divided every 6 hours

Usual Pediatric Dose for Hepatic Encephalopathy

The safety and efficacy of Neomycin Topical (Clobeta-GM) in children less than 18 years of age has not been established. However, the use of Neomycin Topical (Clobeta-GM) may be appropriate is some situations.

1 month to 18 years: 50 to 100 mg/kg/day orally divided every 6 to 8 hours for 5 to 6 days

Usual Pediatric Dose for Hepatic Coma

The safety and efficacy of Neomycin Topical (Clobeta-GM) in children less than 18 years of age has not been established. However, the use of Neomycin Topical (Clobeta-GM) may be appropriate is some situations.

1 month to 18 years: 50 to 100 mg/kg/day orally divided every 6 to 8 hours for 5 to 6 days

Usual Pediatric Dose for Diarrhea

The safety and efficacy of Neomycin Topical (Clobeta-GM) in children less than 18 years of age has not been established. However, the use of Neomycin Topical (Clobeta-GM) may be appropriate is some situations.

Less than 1 month: 50 mg/kg/day orally divided every 6 hours

1 year to 18 years: 50 mg/kg/day orally divided every 6 hours for 2 to 3 days

Renal Dose Adjustments

Patients with impaired renal function have a high risk of developing nephrotoxicity and ototoxicity with oral Neomycin Topical (Clobeta-GM). Use of a less nephrotoxic medication may be a consideration for this patient.

Liver Dose Adjustments

In chronic hepatic insufficiency, it may be necessary to give Neomycin Topical (Clobeta-GM) 4 g daily for an indefinite period, if less toxic drugs cannot be used.

Dose Adjustments

Caution should be used when administering Neomycin Topical (Clobeta-GM) to patients with renal impairment. Dose reduction should be considered in these patients.

Precautions

To minimize the risk of toxicity use the lowest possible dose and the shortest possible treatment period to control the condition. Treatment periods of longer than 2 weeks are not recommended.

Do not use in patients with intestinal obstruction.

Do not use in patients with inflammatory or ulcerative gastrointestinal disease due to the potential for increased gastrointestinal absorption of the drug.

Patients should be monitored for nephrotoxicity and ototoxicity.

Neomycin Topical (Clobeta-GM) should be used with caution in patients with hearing impairment, renal impairment or neuromuscular disorders.

Dialysis

Patients with impaired renal function have a high risk of developing nephrotoxicity and ototoxicity with oral Neomycin Topical (Clobeta-GM). Use of a less nephrotoxic medication may be a consideration for this patient.

See also:
What is the most important information I should know about Clobetasol Topical (Clobeta-GM)?

Hypersensitivity to clobetasol propionate or to any of the excipients of Clobetasol Topical (Clobeta-GM).

Scalp Application: Infections of the scalp.

Cream/Ointment: Primary skin lesions caused by infection with fungi or bacteria; primary cutaneous viral infections (eg, herpes simplex, chickenpox); rosacea; acne vulgaris; pruritus without inflammation; perianal and genital pruritus; perioral dermatitis.

Use in children: Clobetasol Topical (Clobeta-GM) is contraindicated in children <1 year.

Children are more likely to develop local and systemic side effects of topical corticosteroids and in general, require shorter courses and less potent agents than adults.

Care should be taken when using Clobetasol Topical (Clobeta-GM) to ensure the amount applied is the minimum that provides therapeutic benefit.

See also:
What is the most important information I should know about Miconazole Topical (Clobeta-GM)?

When used by a person taking the anticoagulant medication warfarin, Miconazole Topical (Clobeta-GM) may cause an adverse reaction which can lead to excessive bleeding or bruising.

See also:
What is the most important information I should know about Neomycin Topical (Clobeta-GM)?

Neomycin Topical (Clobeta-GM) oral preparations are contraindicated in the presence of intestinal obstruction and in individuals with a history of hypersensitivity to the drug.

Patients with a history of hypersensitivity or serious toxic reaction to other aminoglycosides may have a cross-sensitivity to Neomycin Topical (Clobeta-GM). Neomycin Topical (Clobeta-GM) oral preparations are contraindicated in patients with inflammatory or ulcerative gastrointestinal disease because of the potential for enhanced gastrointestinal absorption of Neomycin Topical (Clobeta-GM).

Use Clobetasol Topical (Clobeta-GM) as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Wash your hands before using Clobetasol Topical (Clobeta-GM). If your fingers are warm, rinse them in cold water and dry before you apply Clobetasol Topical (Clobeta-GM).
• Use the smallest amount of medicine necessary to cover the affected area.
• Turn the can upside down and squirt a small amount of foam (up to the size of a golf ball or about 1½ capfuls) into the cap of the can, onto a clean saucer, or onto another cool, clean surface. You may also squirt it directly onto the affected area. Do not squirt the medicine directly into the hand because it will start to melt immediately upon touching warm skin.
• If you are applying Clobetasol Topical (Clobeta-GM) to the scalp, move the hair away from the affected area and gently rub the medicine into the affected area until the foam disappears. Repeat until the entire affected area of the scalp is treated.
• If you are applying Clobetasol Topical (Clobeta-GM) to other areas, gently rub the medicine into the skin until it disappears.
• Throw away any unused medicine that has been squirted out of the can.
• Wash your hands immediately after using Clobetasol Topical (Clobeta-GM), unless your hands are a part of the treated area.
• Do not use Clobetasol Topical (Clobeta-GM) on your face, groin, or underarms unless your doctor tells you otherwise.
• Do not use Clobetasol Topical (Clobeta-GM) over large areas of the body without first checking with your doctor.
• Do not bandage or wrap the affected area unless directed to do so by your doctor.
• If the can seems warm or the foam seems runny, rinse the can with cool water.
• If you miss a dose of Clobetasol Topical (Clobeta-GM), apply it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Clobetasol Topical (Clobeta-GM).

Use Miconazole Topical (Clobeta-GM) as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Clean the affected area and dry it thoroughly.
• Sprinkle a thin layer of medicine over the entire affected area in the morning and evening unless otherwise directed by your doctor.
• Wash hands immediately after using Miconazole Topical (Clobeta-GM) unless your hands are part of the treated area.
• For athlete's foot, pay special attention to the area between the toes. Wear well-fitting, ventilated shoes, and change your shoes and socks at least once daily.
• To clear up your infection completely, continue using Miconazole Topical (Clobeta-GM) for the full course of treatment even if you feel better in a few days.
• Supervise children in the use of this product.
• If you miss a dose of Miconazole Topical (Clobeta-GM), use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Miconazole Topical (Clobeta-GM).

Use Neomycin Topical (Clobeta-GM) as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Neomycin Topical (Clobeta-GM) by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.
• Take Neomycin Topical (Clobeta-GM) with plenty of water to avoid dehydration.
• Do not take Neomycin Topical (Clobeta-GM) for more than 2 weeks unless advised to do so by your health care provider.
• Take Neomycin Topical (Clobeta-GM) on a regular schedule to get the most benefit from it.
• To clear up your infection completely, use Neomycin Topical (Clobeta-GM) for the full course of treatment. Keep using it even if you feel better in a few days.
• If you miss a dose of Neomycin Topical (Clobeta-GM), take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once. If more than one dose is missed, contact your health care provider.

Ask your health care provider any questions you may have about how to use Neomycin Topical (Clobeta-GM).

Clobetasol Topical (Clobeta-GM) is used to treat itching, redness, dryness, inflammation, and discomfort of various scalp and skin conditions, including immune-mediated skin disease with red scaly patches (psoriasis).

Miconazole is used to treat skin infections such as athlete's foot, jock itch, ringworm, and other fungal skin infections (candidiasis). This medication is also used to treat a skin condition known as pityriasis (tinea versicolor), a fungal infection that causes a lightening or darkening of the skin of the neck, chest, arms, or legs. Miconazole is an azole antifungal that works by preventing the growth of fungus.

How to use Miconazole Topical (Clobeta-GM) topical

Use this medication on the skin only. Clean and thoroughly dry the area to be treated. Apply this medication to the affected skin, usually twice a day or as directed by your doctor. If you are using the spray form, shake the bottle well before applying. Dosage and length of treatment depends on the type of infection being treated. Do not apply this more often than prescribed. Your condition will not clear faster, but side effects may be increased.

Apply enough medication to cover the affected area and some of the surrounding skin. After applying this medication, wash your hands. Do not wrap, cover or bandage the area unless directed to do so by your doctor.

Do not apply this medication in the eyes, nose, mouth, or vagina.

Use this medication regularly in order to get the most benefit from it. Remember to use it at the same times each day.

Continue to use this medication until the full prescribed amount is finished, even if symptoms disappear after starting miconazole. Stopping the medication too early may allow the fungus to continue to grow, which may result in a relapse of the infection.

Inform your doctor if your condition persists or worsens.

Neomycin Topical (Clobeta-GM) is used topically to prevent or treat skin infections caused by bacteria.

See also:
What other drugs will affect Clobetasol Topical (Clobeta-GM)?

Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid combination

Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. Monitor therapy

Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Monitor therapy

Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Consider therapy modification

Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. Monitor therapy

See also:
What other drugs will affect Miconazole Topical (Clobeta-GM)?

The effects of some drugs can change if you take other drugs or herbal products at the same time. This can increase your risk for serious side effects or may cause your medications not to work correctly. These drug interactions are possible, but do not always occur. Your doctor or pharmacist can often prevent or manage interactions by changing how you use your medications or by close monitoring.

To help your doctor and pharmacist give you the best care, be sure to tell your doctor and pharmacist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products) before starting treatment with this product. While using this product, do not start, stop, or change the dosage of any other medicines you are using without your doctor's approval.

Some products that may interact with this drug include: warfarin.

Some products that may increase the risk of vaginal yeast infections include antibiotics, corticosteroids (such as prednisone), and drugs that suppress the immune system (such as cyclosporine, methotrexate).

This document does not contain all possible drug interactions. Keep a list of all the products you use. Share this list with your doctor and pharmacist to lessen your risk for serious medication problems.

See also:
What other drugs will affect Neomycin Topical (Clobeta-GM)?

Acarbose: Neomycin Topical (Clobeta-GM) may enhance the adverse/toxic effect of Acarbose. Neomycin Topical (Clobeta-GM) may decrease the metabolism of Acarbose. Monitor therapy

Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy

Arbekacin: May enhance the nephrotoxic effect of Aminoglycosides. Arbekacin may enhance the ototoxic effect of Aminoglycosides. Monitor therapy

Ataluren: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, an increased risk of nephrotoxicity may occur with the concomitant use of ataluren and aminoglycosides. Avoid combination

Bacitracin (Systemic): Neomycin Topical (Clobeta-GM) may enhance the nephrotoxic effect of Bacitracin (Systemic). Avoid combination

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Monitor therapy

Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives. Monitor therapy

Botulinum Toxin-Containing Products: Aminoglycosides may enhance the neuromuscular-blocking effect of Botulinum Toxin-Containing Products. Monitor therapy

Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides. Monitor therapy

CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin. Monitor therapy

Cardiac Glycosides: Aminoglycosides may decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Monitor therapy

Cefazedone: May enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy

Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy

Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy

Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy

Cephalothin: May enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy

Cephradine: May enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy

CISplatin: May enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy

Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Management: Avoid coadministration of colistimethate and aminoglycosides whenever possible due to the risk of nephrotoxicity and neuromuscular blockade. If coadministration cannot be avoided, monitor renal and neuromuscular function. Consider therapy modification

CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Monitor therapy

Distigmine: Aminoglycosides may diminish the therapeutic effect of Distigmine. Monitor therapy

Foscarnet: May enhance the nephrotoxic effect of Aminoglycosides. Avoid combination

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Monitor therapy

Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity. Monitor therapy

Mannitol (Systemic): May enhance the nephrotoxic effect of Aminoglycosides. Avoid combination

Mecamylamine: Aminoglycosides may enhance the neuromuscular-blocking effect of Mecamylamine. Avoid combination

Methoxyflurane: Aminoglycosides may enhance the nephrotoxic effect of Methoxyflurane. Avoid combination

Neuromuscular-Blocking Agents: Aminoglycosides may enhance the therapeutic effect of Neuromuscular-Blocking Agents. Monitor therapy

Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants. Monitor therapy

Oxatomide: May enhance the ototoxic effect of Aminoglycosides. Monitor therapy

Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Bacampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Benzathine; Penicillin V Potassium. Consider therapy modification

Regorafenib: Neomycin Topical (Clobeta-GM) may decrease serum concentrations of the active metabolite(s) of Regorafenib. Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Consider therapy modification

SORAfenib: Neomycin Topical (Clobeta-GM) may decrease the serum concentration of SORAfenib. Monitor therapy

Tenofovir Products: Aminoglycosides may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides. Monitor therapy

Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy

Vitamin K Antagonists (eg, warfarin): Neomycin Topical (Clobeta-GM) may enhance the anticoagulant effect of Vitamin K Antagonists. Monitor therapy

See also:
What are the possible side effects of Clobetasol Topical (Clobeta-GM)?

In a controlled pharmacokinetic study, 5 of 13 subjects experienced reversible suppression of the adrenals at any time during the 14 days of Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam therapy to at least 20% of the body surface area. Of the 13 subjects studied, 1 of 9 with psoriasis were suppressed after 14 days and all 4 of the subjects with atopic dermatitis had abnormal cortisol levels indicative of adrenal suppression at some time after starting therapy with Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam.

Table 3: Subjects with reversible HPA axis suppression at any time during treatment

Systemic absorption of topical corticosteroids has produced reversible adrenal suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

In a controlled clinical trial (188 subjects) with Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam in subjects with psoriasis of the scalp, there were no localized scalp adverse reactions reported in the Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam treated subjects. In two controlled clinical trials (360 subjects) with Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam in subjects with psoriasis of non-scalp regions, localized adverse events that occurred in the Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam treated subjects included application site burning (10%), application site dryness ( < 1%), and other application site reactions (4%).

In larger controlled trials with other clobetasol propionate formulations, the most frequently reported local adverse reactions have included burning, stinging, irritation, pruritus, erythema, folliculitis, cracking and fissuring of the skin, numbness of the fingers, skin atrophy, and telangiectasia (all less than 2%).

The following additional local adverse reactions have been reported with topical corticosteroids, but they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids such as Clobetasol Topical (Clobeta-GM) (clobetasol propionate) Foam. These reactions are listed in an approximate decreasing order of occurrence: dryness, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae, and miliaria.

See also:
What are the possible side effects of Miconazole Topical (Clobeta-GM)?

Applies to Miconazole Topical (Clobeta-GM): topical cream, topical gel/jelly, topical kit, topical lotion, topical ointment, topical powder, topical spray, topical tablet effervescent, topical tincture

In addition to its needed effects, some unwanted effects may be caused by Miconazole Topical (Clobeta-GM) (the active ingredient contained in Miconazole Topical (Clobeta-GM)). In the event that any of these side effects do occur, they may require medical attention.

Severity: Moderate

If any of the following side effects occur while taking Miconazole Topical (Clobeta-GM), check with your doctor or nurse as soon as possible:

• Blistering, burning, redness, skin rash, or other sign of skin irritation not present before use of this medicine

See also:
What are the possible side effects of Neomycin Topical (Clobeta-GM)?

Allergic reaction, Itching, Skin redness, Eye infection, Skin rash, Fever